EA199800971A1 - Способ лечения новообразований, вкючающий применение ингибиторов протеиназы с - Google Patents

Способ лечения новообразований, вкючающий применение ингибиторов протеиназы с

Info

Publication number
EA199800971A1
EA199800971A1 EA199800971A EA199800971A EA199800971A1 EA 199800971 A1 EA199800971 A1 EA 199800971A1 EA 199800971 A EA199800971 A EA 199800971A EA 199800971 A EA199800971 A EA 199800971A EA 199800971 A1 EA199800971 A1 EA 199800971A1
Authority
EA
Eurasian Patent Office
Prior art keywords
formations
treatment
proteinase inhibitors
pkc
isoenzyme
Prior art date
Application number
EA199800971A
Other languages
English (en)
Inventor
Майкл Р. Джироусек
Лоренс Э. Страмм
Дуглас Кирк Вэйс
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA199800971A1 publication Critical patent/EA199800971A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A61K31/787—Polymers containing nitrogen containing heterocyclic rings having nitrogen as a ring hetero atom
    • A61K31/79—Polymers of vinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Предложен способ лечения новообразований, конкретно, с использованием селективного по отношению к β-изозиму (β-изоферменту) ингибитора протеинкиназы С (ПКС), (S)-3,4-[N,N'-1,1' {(2"-этокси)-3'''(0)-4'''-(N, N-диметиламино)-бутан)-бис-(3,3'-индолил)]-1(Н)-пиррол-2,5-диона или одной из его солей, такие ингибиторы ПКС повышают клиническую эффективность онколитических средств и лучевой терапии.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA199800971A 1996-05-01 1997-05-01 Способ лечения новообразований, вкючающий применение ингибиторов протеиназы с EA199800971A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1665896P 1996-05-01 1996-05-01
US08/841,738 US6232299B1 (en) 1996-05-01 1997-04-30 Use of protein kinase C inhibitors to enhance the clinical efficacy of oncolytic agents and radiation therapy
PCT/US1997/007801 WO1997040842A1 (en) 1996-05-01 1997-05-01 Use of protein kinase c inhibitors to enhance the clinical efficacy of oncolytic agents and radiation therapy

Publications (1)

Publication Number Publication Date
EA199800971A1 true EA199800971A1 (ru) 1999-04-29

Family

ID=26688914

Family Applications (1)

Application Number Title Priority Date Filing Date
EA199800971A EA199800971A1 (ru) 1996-05-01 1997-05-01 Способ лечения новообразований, вкючающий применение ингибиторов протеиназы с

Country Status (15)

Country Link
US (3) US6232299B1 (ru)
EP (1) EP0914135A4 (ru)
JP (1) JP2000510828A (ru)
KR (1) KR20000065223A (ru)
AU (1) AU718098B2 (ru)
BR (1) BR9710704A (ru)
CA (1) CA2253263A1 (ru)
CZ (1) CZ344398A3 (ru)
EA (1) EA199800971A1 (ru)
HU (1) HUP0100285A3 (ru)
IL (1) IL126768A0 (ru)
NO (1) NO985065L (ru)
NZ (1) NZ332563A (ru)
PL (1) PL330862A1 (ru)
WO (1) WO1997040842A1 (ru)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6147107A (en) * 1998-12-20 2000-11-14 Virginia Commonwealth University Specific inhibition of the P42/44 mitogen activated protein (map) kinase cascade sensitizes tumor cells
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
EP1158985B1 (en) 1999-01-13 2011-12-28 Bayer HealthCare LLC OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS
PT1478358E (pt) 2002-02-11 2013-09-11 Bayer Healthcare Llc Tosilato de sorafenib para o tratamento de doenças caracterizadas por angiogénese anormal
JP2007511203A (ja) 2003-05-20 2007-05-10 バイエル、ファーマシューテイカルズ、コーポレイション キナーゼ阻害活性を有するジアリール尿素
DE602004010407T2 (de) 2003-07-23 2008-10-16 Bayer Pharmaceuticals Corp., West Haven Fluorsubstituierter omega-carboxyaryldiphenylharnstoff zur behandlung und prävention von krankheiten und leiden
AU2004282219C1 (en) * 2003-10-15 2009-12-17 Osi Pharmaceuticals, Inc. Imidazo [1, 5 - a] pyrazine tyrosine kinase inhibitors
SG163576A1 (en) 2004-04-02 2010-08-30 Osi Pharm Inc 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
AR053090A1 (es) 2004-07-20 2007-04-25 Osi Pharm Inc Imidazotriazinas como inhibidores de proteina quinasas y su uso para la preparacion de medicamentos
US20060228734A1 (en) * 2005-03-18 2006-10-12 Applera Corporation Fluid processing device with captured reagent beads
WO2006108270A1 (en) * 2005-04-11 2006-10-19 Pharmagap Inc. Inhibitors of protein kinases and uses thereof
US7566721B2 (en) * 2005-08-08 2009-07-28 Osi Pharmaceuticals, Inc. Substituted thienol[2,3-d]pyrimidines as kinase inhibitors
US20080214521A1 (en) * 2005-08-09 2008-09-04 Martin Schuler Sensitization of Drug-Resistant Lung Caners to Protein Kinase Inhibitors
CA2622867A1 (en) 2005-09-16 2007-03-22 Schering Corporation Pharmaceutical compositions and methods using temozolomide and a protein kinase inhibitor
AR057960A1 (es) * 2005-12-02 2007-12-26 Osi Pharm Inc Inhibidores de proteina quinasa biciclicos
US8575164B2 (en) * 2005-12-19 2013-11-05 OSI Pharmaceuticals, LLC Combination cancer therapy
WO2009025847A2 (en) * 2007-08-21 2009-02-26 Nodality, Inc. Methods for diagnosis, prognosis and methods of treatment
EP2050441A1 (en) * 2007-10-19 2009-04-22 Université Victor Segalen Bordeaux 2 Use of beta blocker for the manufacture of a medicament for the treatment of hemangiomas
JP2011510018A (ja) * 2008-01-18 2011-03-31 オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド 癌治療のためのイミダゾピラジノール誘導体
US20090269773A1 (en) * 2008-04-29 2009-10-29 Nodality, Inc. A Delaware Corporation Methods of determining the health status of an individual
EP2283020B8 (en) * 2008-05-19 2012-12-12 OSI Pharmaceuticals, LLC Substituted imidazopyr-and imidazotri-azines
WO2010006291A1 (en) 2008-07-10 2010-01-14 Nodality, Inc. Methods for diagnosis, prognosis and treatment
US8399206B2 (en) * 2008-07-10 2013-03-19 Nodality, Inc. Methods for diagnosis, prognosis and methods of treatment
WO2010123792A1 (en) 2009-04-20 2010-10-28 Osi Pharmaceuticals, Inc. Preparation of c-pyrazine-methylamines
EP2427192A1 (en) * 2009-05-07 2012-03-14 OSI Pharmaceuticals, LLC Use of osi-906 for treating adrenocortical carcinoma
US20100297676A1 (en) * 2009-05-20 2010-11-25 Nodality, Inc. Methods for diagnosis, prognosis and methods of treatment
SG192669A1 (en) 2011-02-11 2013-09-30 Glaxosmithkline Ip Dev Ltd Cathepsin c inhibitors
WO2012173841A1 (en) * 2011-06-07 2012-12-20 Dana-Farber Cancer Institute, Inc. Biomarker for pkc-iota activity and methods of using same

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4937232A (en) 1986-09-15 1990-06-26 Duke University Inhibition of protein kinase C by long-chain bases
SK278989B6 (sk) 1988-02-10 1998-05-06 F. Hoffmann-La Roche Ag Substituované pyroly, ich použitie na výrobu lieči
DE3827974A1 (de) * 1988-08-18 1990-02-22 Boehringer Mannheim Gmbh Kombinationspraeparate von proteinkinase-c-inhibitoren mit lipiden, lipid-analoga, cytostatica oder inhibitoren von phospholipasen
US4990519A (en) 1988-10-24 1991-02-05 Merrell Dow Pharmaceuticals Method of using quinolyloxazole-2-ones as proteinkinase C inhibitors
US5552391A (en) 1990-01-16 1996-09-03 La Jolla Pharmaceutical Company Chemically-defined non-polymeric valency platform molecules and conjugates thereof
US5344841A (en) * 1990-11-02 1994-09-06 Sphinx Pharmaceuticals Corporation Bis-(hydroxylakylamino)-anthraquinone inhibitors of protein kinase C
US5141957A (en) 1990-11-02 1992-08-25 Sphinx Pharmaceuticals Corporation 1,4-bis-(amino-hydroxyalkylamino)-anthraquinones for inhibiting protein kinase c
US5204370A (en) 1990-11-05 1993-04-20 Sphinx Pharmaceuticals Corporation Bis-(hydroxyalkylamino)-anthraquinone inhibitors of protein kinase C
JPH06510280A (ja) * 1991-08-22 1994-11-17 スフィンクス・ファーマスーティカルズ・コーポレーション タンパクキナーゼｃ阻害および新規化合物バラノール
US5216014A (en) 1991-09-10 1993-06-01 Sphinx Pharmaceuticals Corporation Furo-coumarinsulfonamides as protein kinase C inhibitors
US5270310A (en) 1991-12-13 1993-12-14 Sphinx Pharmaceuticals Corporation N-aminoalkyl amide inhibitors of protein kinase C
US5621101A (en) 1992-07-24 1997-04-15 Cephalon, Inc. Protein kinase inhibitors for treatment of neurological disorders
US5461146A (en) 1992-07-24 1995-10-24 Cephalon, Inc. Selected protein kinase inhibitors for the treatment of neurological disorders
CA2174431C (en) 1993-10-18 2005-12-06 Tomas Hudlicky Synthesis of sphingosines
DK0657411T3 (da) 1993-12-07 1999-11-15 Lilly Co Eli Forbedret syntese af bisindolylmaleimider
US5624949A (en) * 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
US5545636A (en) 1993-12-23 1996-08-13 Eli Lilly And Company Protein kinase C inhibitors
DK0817627T3 (da) * 1993-12-23 2005-06-06 Lilly Co Eli Inhibitorer af proteinkinase C
WO1995032975A1 (en) * 1994-06-01 1995-12-07 Ciba-Geigy Ag Indolocarbazole derivatives for sensitizing multidrug-resistant cells to antitumor agents
US5481003A (en) 1994-06-22 1996-01-02 Eli Lilly And Company Protein kinase C inhibitors
US5491242A (en) 1994-06-22 1996-02-13 Eli Lilly And Company Protein kinase C inhibitors
US5432198A (en) * 1994-08-18 1995-07-11 Sphinx Pharmaceuticals Corporation Vicinal-substituted carbocyclic compounds as therapeutic agents
US5616577A (en) 1994-08-25 1997-04-01 Smithkline Beecham Corporation Protein Kinase C inhibitor

Also Published As

Publication number Publication date
IL126768A0 (en) 1999-08-17
NO985065D0 (no) 1998-10-30
EP0914135A4 (en) 2001-01-24
NZ332563A (en) 2000-08-25
WO1997040842A1 (en) 1997-11-06
AU3000297A (en) 1997-11-19
PL330862A1 (en) 1999-06-07
KR20000065223A (ko) 2000-11-06
JP2000510828A (ja) 2000-08-22
CA2253263A1 (en) 1997-11-06
CZ344398A3 (cs) 1999-07-14
AU718098B2 (en) 2000-04-06
US20010001791A1 (en) 2001-05-24
US6232299B1 (en) 2001-05-15
HUP0100285A2 (hu) 2001-09-28
US6288053B1 (en) 2001-09-11
BR9710704A (pt) 1999-08-17
HUP0100285A3 (en) 2003-05-28
US6486179B2 (en) 2002-11-26
NO985065L (no) 1998-12-28
EP0914135A1 (en) 1999-05-12

Similar Documents

Publication Publication Date Title
EA199800971A1 (ru) Способ лечения новообразований, вкючающий применение ингибиторов протеиназы с
NO985066L (no) Terapeutisk behandling for VEGF-relaterte sykdommer
EA199800970A1 (ru) Терапевтическое лечение глазных заболеваний, связанных с фактором роста сосудистого эндотелия
DE69833223D1 (de) 4-aminothiazol derivate, deren herstellung und deren verwendung als inhibitoren cyclin-abhängiger kinasen
EE05003B1 (et) Dihdro-1,3,5-triasiinamino derivaadid ja nende kasutamine ravis
AR002157A1 (es) Uso de una dosis inmunizante eficaz de esporozoitos o merozoitos de eimeria vivos, o una mezcla de los mismos
NO994330L (no) Metode for behandling av en tumor
ATE315933T1 (de) Therapeutische behandlung von kardiovaskularen krankheiten
EA199900245A1 (ru) Использование ингибиторов протеинкиназы с для получения лекарственного препарата для лечения спида
NZ334609A (en) Use of inhibitors of the beta isozyme of protein kinase C for treatment of sexual dysfunctions in mammals
EP0940141A3 (en) Use of PKC inhibitors for the manufacture of a medicament for the treatment of cytomegalovirus infection
EP0940142A3 (en) Use of PKC inhibitors for the manufacture of a medicament for the treatment of autoimmune diseases
EA199900243A1 (ru) Применение ингибиторов протеинкиназы с для производства лекарственного препарата для лечения инфекции, вызванной человеческим т-клеточным лимфотропным вирусом типа 1
EP0940143A3 (en) Use of PKC-inhibitors for the manufacture of a medicament for the treatment of asthma
EA199900244A1 (ru) Применение ингибиторов протеинкиназы с для производства лекарственных препаратов для лечения заболеваний центральной нервной системы, связанных с вич инфекцией
DE69935881D1 (de) Bis-Indolylmaleimide zur therapeutischen Behandlung von Nieren-Funktionsstörungen
IT1284603B1 (it) Grippo mandrino e mozzo di guida migliorato per scope cilindriche